MONITORING OF ADVERSE DRUG REACTIONS IN PAEDIATRIC ASTHMA PATIENTS ATTENDING A PRIVATE HOSPITAL

Sukhmeen Kaur, Bhagya. M. Sattigeri, Deepali Jaybhaye, Sumeet Patni

Abstract


Background of the study: Adverse drug reactions (ADR) constitute a significant health problem in children. Pharmacotherapy of asthma includes prolonged multidrug therapy, which results in its association with different ADRs. Studies involving ADR monitoring in paediatric patients of asthma are limited. Therefore, this study was planned to observe the occurrence of the adverse drug reactions associated with pharmacotherapy of asthma in children.

Materials and Methods: After the institutional ethical approval, an observational, non-interventional and cross-sectional study was conducted in pediatric patients of bronchial asthma in outpatient as well as inpatient setting of a private hospital in Aurangabad from November 2017 to March 2019. All Asthmatic children presenting with adverse drug reactions were studied. All relevant data like patient’s demographic details, type of ADR, drug suspected to cause ADR, body system affected by the ADR were extracted. The causality of ADRs was then assessed by WHO-UMC scale and Naranjo’s scale. Also, modified Hartwig and Siegel’s scale was utilized to assess the severity of recorded ADRs.

Results: Out of total 330 asthmatic children that attended the hospital during the study period, 41 children presented with ADRs. The incidence rate of ADRs was found to be 12.42%. The percentage of ADRs was the highest (43.9%) in patients aged between 5 to 8 years and majority of them were males. The most commonly occurring ADRs were headache (14.63%), sore throat (14.63%), tachycardia (12.19%), dryness of mouth (9.75%), cough (9.75%), drowsiness (7.31%) and oral candidiasis (7.31%). There were no severe reactions, 85.36% ADRs were mild and only 14.63% were moderate in their level of severity. Causality analysis revealed that about 41.46% ADRs were probable and 58.53% were possible.  None of the reported ADR was found to be fatal, life threatening or needed hospital admission for management.

Conclusion: This study highlights the need of rigid ADR monitoring in paediatric asthma patients to ensure safe pharmacotherapy. Adherence to pharmacovigilance guidelines and practices will not only reduce the incidence of ADRs but also reduce cost. Keeping this in mind, various pharmacovigilance awareness programs should be implemented to sensitize health care professionals about spontaneous reporting of ADRs.


Keywords


Adverse drug reactions, Asthma, Pediatrics, Anti-asthmatic drugs, Pharmacovigilance, causality

Full Text:

PDF

References


Elzagallaai AA, Greff M, Rieder MJ. Adverse drug reactions in children: the double-edged sword of therapeutics. Clin Pharmacol Ther. 2017;101(6):725–35.

Wester K, Jonsson AK, Spigset O, Druid H, Hagg S. Incidence of fatal adverse drug reactions: a population-based study. Br J Clin Pharmacol. 2008; 65: 573–579.

Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279:1200–5.

Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001; 52:77–83.

Temple ME, Robinson RF, Miller JC, Hayes JR, Nahata MC. Frequency and preventability of adverse drug reactions in paediatric patients. Drug Saf. 2004; 27:819–29.

Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: A systematic review of prospective observational studies. Ann Pharmacother 2008; 42:1017-25.

Smyth RM, Gargon E, Kirkham J, et al. Adverse drug reactions in children--a systematic review. PLoS One. 2012;7(3): e24061. doi:10.1371/ journal. pone. 0024061

Kohli SK, Sattigeri BM. Adverse drug reactions in pediatric asthma patients attending a tertiary care teaching hospital. 2018; 8 (7): 44-46.

GINA report. Global Strategy for Asthma Management and Prevention, 2011, http://www.ginasthma.org/

Braman SS. The global burden of asthma. Chest. 2006;130 1 Suppl:4S-12.

Whealth reports 2001. Fifty facts from the world health report 1998: Global Health Situation and Trends 1955-2025. WHO. 2001

Ferrante G, La Grutta S. The Burden of Pediatric Asthma. Front Pediatr. 2018; 6:186.

International study of Bronchial Asthma and allergies in childhood (ISAAC) Worldwide variations in the prevalence of Bronchial Asthma symptoms. Euro Respir J. 1998; 12: 315–35.

Pal R, Dahal S, Pal S. Prevalence of bronchial asthma in Indian children. Indian J Community Med. 2009;34(4):310–316.

Sun HL, Kao YH, Chou MC, Lu TH, Lue KH. Differences in the prescription patterns of anti-asthmatic medications for children by paediatricians, family physicians and physicians of other specialties. J Formos Med Assoc. 2006 Apr; 105(4):277-83.

Bhosale U, Jaiswal S, Yegnanarayan R, Godbole G. A pharmacovigilance study of anti-asthmatic agents in patients of bronchial asthma at a tertiary care hospital. J Clin Exp Res 2013; 1: 26-30.

Black C, Tagiyeva-Milne N, Helms P, Moir D. Pharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review. Br J Clin Pharmacol. 2015;80(4):844–854.

Star K, Noren GN, Nordin K, Edwards IR. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Safety. 2011; 34(5): 415-428.

Al Tajir GK, Kelly WN. Epidemiology, comparative methods of detection, and preventability of adverse drug events. Ann Pharmacother. 2005; 39:1169–74.

Kunac DL, Kennedy J, Austin N, Reith D. Incidence, preventability, and impact of adverse drug events (ADEs) and potential ADEs in hospitalized children in New Zealand: A prospective observational cohort study. Pediatric Drugs. 2009; 11: 153–60.

WHO policy perspective of medicines, Pharmacovigilance: Ensuring the safe use of medicines. Geneva: WHO; 2004. p. 1222-39.

Malcolm G, Kavita D, Akanksha S, Preeti G. Pattern of adverse drug reactions to antibiotics commonly prescribed in department of medicine and pediatrics in a tertiary care teaching hospital, Ghaziabad. JAPS. 2015; 5(4):78–82.

Jamali AN, Aqil M, Alam MS, Pillai KK, Kapur P. A pharmacovigilance study on patients of bronchial asthma in a teaching hospital. J Pharm Bioallied Sci. 2010;2(4):333–336.

Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJ, Aronson JK, et al. Adverse drug reactions in a hospital general medicine unit meriting notification to the Committee on Safety of Medicines. Br J Cln Pharmacol. 1996; 42: 423–9.

Sindhu AR, Sebastian M, Panicker PR, Muthusamy S, Nallasamy V5, Ramanathan R, Perumal S. A study on adverse drug reactions in hospitalized pediatric patients in a Tertiary Care Hospital. J Appl Pharm Sci, 2019; 9(09):072–076.

Choi IS. Gender-specific asthma treatment. Allergy Asthma Immunol Res. 2011;3(2):74–80.

Barranco P, Lopez-Serrano MC. General and epidemiological aspects of allergic drug reactions. Clin Exp Allergy 1998; 28:61-2.

Riedl MA, Casillas AM. Adverse drug reactions: Types and treatment options. Am Fam Physician 2003; 68:1781-91.

Gawali UP, Deshkar A. Pharmacovigilance study of anti-asthmatic agents in patients of bronchial asthma at a tertiary care centre. Int. J. Adv. Res.2017; 5(3), 1867-71.

Bajaj A, Balakrishna S, Sawarkar S. Assessment of therapeutic performances of inhalation aerosols and clinical pharmacist’s services in PFT lab. Indian J Hosp Pham. 1999; 36:138–142.

Dutch Children's Formulary . (2016). Avaliable at: https://www.kinderformularium.nl

Al-Moamary MS, Alhaider SA, Alangari AA, Al Ghobain MO, Zeitouni MO, Idrees MM, Alanazi AF, Al-Harbi AS, Yousef AA, Alorainy HS, Al-Hajjaj MS. The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children. Ann Thorac Med 2019; 14: 3-48

Alam S, Mushtaq M. Antibiotic associated diarrhea in children. Indian Pediatr 2009; 46: 491– 6.


Refbacks

  • There are currently no refbacks.